ArticleJournal of diabetes research2026
The Link Between Serum Copper and Diabetic Kidney Disease: A Plasma Proteomic Perspective.
Article in Journal of diabetes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Link Between Serum Copper and Diabetic Kidney Disease: A Plasma Proteomic Perspective.Journal of diabetes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDiabetic kidney disease (DKD) is a significant microvascular complication of diabetes, accounting for the majority of cases of end-stage renal disease. Copper, an essential trace element, has been identified as a factor closely associated with the onset and progression of DKD. However, the precise causal link between serum copper levels and DKD, along with the mechanisms governing their association, remains unclear.
methodsThis study employed Mendelian randomization (MR) analysis based on large-scale GWAS data to explore the causal relationship between serum copper levels and DKD. Additionally, mediation analysis was conducted using plasma proteomic data, complemented by enrichment analysis to explore the mediating metabolic pathways or signaling pathways through which serum copper may mediate the development of DKD.
resultsMR results demonstrated that elevated serum copper levels significantly increased the risk of DKD (OR = 1.123, p < 0.001). Additionally, no evidence of pleiotropy or heterogeneity was detected, which provides further assurance of the reliability of results. Protein mediation analysis identified 10 plasma proteins, including FABP, Netrin-1, and glutathione S-transferase A4 as critical mediators in copper-driven DKD, with mediation effects ranging from 6.42% to 28.02%. Following the identification of these 10 mediator proteins, 11 intermediary pathways that mediated the effect of serum copper levels on the onset of DKD were identified.
conclusionThis study elucidates the causal effect of copper levels on DKD and reveals the underlying mechanism by which increased serum copper levels lead to the development of DKD, offering novel insights and potential therapeutic targets for DKD prevention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.